General Information
Version
6.4
Revision date
2024-03-06
Product name
Yttrium(III) iodide
CAS No.
13470-38-7
REACH No
A
Emergency telephone
+(47)-22591300, +(47)-21930678
Icons in SDS
Company Information
company name
Merck Life Science AS
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H317, H334, H351
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture Respiratory sensitization, H334: May cause allergy or asthma Category 1) symptoms or breathing difficulties if inhaled Skin sensitization, (Category 1) H317: May cause an allergic skin reaction Carcinogenicity, (Category 2) H351: Suspected of causing cancer
Signal word
Danger
Hazard statements
H317 May cause an allergic skin reaction. H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. H351 Suspected of causing cancer.
Precautionary statements
P202 Do not handle until all safety precautions have been read and understood. P261 Avoid breathing dust. P272 Contaminated work clothing should not be allowed out of the workplace. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P302 + P352 IF ON SKIN: Wash with plenty of water. P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Supplemental label elements
none
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
2.1 Classification of the substance or mixture
Respiratory sensitization, H334: May cause allergy or asthma (Category 1) symptoms or breathing difficulties if inhaled. Skin sensitization, (Category 1) H317: May cause an allergic skin reaction. Carcinogenicity, (Category 2) H351: Suspected of causing cancer.
